Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.60 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 12/20 | 0.59 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16516711 | 0.92 | HDAC8 (0.67) | PARP10PARP15HDAC8LY96HDAC6 | |
| SCHEMBL18538449 | 0.83 | HDAC8 (0.71) | HDAC8LY96HDAC3HDAC1NCOR2 | |
| SCHEMBL16516442 | 0.79 | HDAC8 (0.84) | HDAC8LY96HDAC6MEN1KMT2A | |
| SCHEMBL16516641 | 0.78 | HDAC8 (0.73) | HDAC8LY96HDAC6MEN1KMT2A | |
| SCHEMBL18542270 | 0.77 | LY96 (0.74) | HDAC8LY96HDAC6MEN1KMT2A | |
| SCHEMBL16516649 | 0.77 | HDAC8 (0.72) | HDAC8LY96HDAC6MEN1KMT2A | |
| SCHEMBL16516504 | 0.75 | PTGER3 (0.53) | PARP10PARP15MEN1KMT2ANPC1 | |
| SCHEMBL16516503 | 0.75 | PTGER3 (0.53) | PARP10PARP15MEN1KMT2ANPC1 | |
| SCHEMBL16516560 | 0.74 | HDAC8 (0.87) | HDAC8LY96HDAC3HDAC1NCOR2 | |
| SCHEMBL16516643 | 0.74 | HDAC8 (1.00) | HDAC8HDAC6HDAC3HDAC1NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190322617-A1 | HDAC8 INHIBITORS FOR TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-10-24 | — | — | US | disclosed |
| US-10308596-B2 | HDAC8 inhibitors for treating cancer | CITY OF HOPE (US) | 2019-06-04 | — | — | US | disclosed |
| US-20170050922-A2 | HDAC8 INHIBITORS FOR TREATING CANCER | CITY OF HOPE | 2017-02-23 | — | — | US | disclosed |
| EP-3035924-A2 | HDAC8 INHIBITORS FOR TREATING CANCER | City of Hope (US) | 2016-06-29 | — | — | EP | disclosed |
| WO-2015026935-A2 | HDAC8 INHIBITORS FOR TREATING CANCER | CITY OF HOPE (US) | 2015-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050922-A2 | HDAC8 INHIBITORS FOR TREATING CANCER | HDAC8, HDAC1, HDAC7 | PARP10 1020/4885PARP15 665/4885HDAC8 1/4885 |
| US-10308596-B2 | HDAC8 inhibitors for treating cancer | HDAC8, HDAC1, HDAC7 | PARP10 1020/4885PARP15 665/4885HDAC8 1/4885 |
| US-20190322617-A1 | HDAC8 INHIBITORS FOR TREATING CANCER | HDAC8, HDAC1, HDAC7 | PARP10 1020/4885PARP15 665/4885HDAC8 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.